Processa Pharmaceuticals (PCSA) Prepaid Assets (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Prepaid Assets came in at $247363.0 in Q1 2026, down 71.26% YoY from $860814.0 in Q1 2025, and up 84.71% on a QoQ basis from $133919.0 in Q4 2025.
Processa Pharmaceuticals (PCSA) Prepaid Assets (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Prepaid Assets data on file, last reported at $247363.0 in Q1 2026.
- Quarterly Prepaid Assets fell 71.26% year-over-year to $247363.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $247363.0 (down 71.26% YoY) and the FY2025 annual result came in at $133919.0, down 80.53% from the prior year.
- Prepaid Assets climbed to $247363.0 in Q1 2026, from $133919.0 in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $2.0 million in Q1 2022 to a low of $133919.0 in Q4 2025.
- A 5-year average of $1.1 million and a median of $1.0 million in 2023 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2024 — Prepaid Assets soared 85.97% — and 2025, when it sank 88.61%.
- Tracing PCSA's Prepaid Assets over 5 years: stood at $1.9 million in 2022, then slumped by 50.81% to $926300.0 in 2023, then declined by 25.74% to $687829.0 in 2024, then sank by 80.53% to $133919.0 in 2025, then surged by 84.71% to $247363.0 in 2026.
- The last three Prepaid Assets figures came in at $247363.0 (Q1 2026), $133919.0 (Q4 2025), and $278342.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 247,363.00 |
| Dec 31, 2025 | 133,919.00 |
| Sep 30, 2025 | 278,342.00 |
| Jun 30, 2025 | 217,201.00 |
| Mar 31, 2025 | 860,814.00 |
| Dec 31, 2024 | 687,829.00 |
| Sep 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | 1.91 Mn |
| Mar 31, 2024 | 857,635.00 |
| Dec 31, 2023 | 926,300.00 |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 1.22 Mn |
| Mar 31, 2023 | 1.48 Mn |
| Dec 31, 2022 | 1.88 Mn |
| Sep 30, 2022 | 1.83 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Mar 31, 2022 | 1.99 Mn |
| Dec 31, 2021 | 1.76 Mn |
| Sep 30, 2021 | 1.51 Mn |
| Jun 30, 2021 | 1.66 Mn |